[1] RUDWALEIT M, BAETEN D. Ankylosing spondylitis and bowel disease[J]. Best Pract Res Clin Rheumatol,2006,20(3):451-471. doi:  10.1016/j.berh.2006.03.010
[2] SMALE S, NATT R S, ORCHARD T R, et al. Inflammatory bowel disease and spondylarthropathy[J]. Arthritis Rheum,2001,44(12):2728-2736. doi:  10.1002/1529-0131(200112)44:12<2728::AID-ART459>3.0.CO;2-8
[3] BRAUN J, BARALIAKOS X, LISTING J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents[J]. Arthritis Rheum,2007,57(4):639-647. doi:  10.1002/art.22669
[4] MOUDGIL K D, CHOUBEY D. Cytokines in autoimmunity: role in induction, regulation, and treatment[J]. J Interferon Cytokine Res,2011,31(10):695-703. doi:  10.1089/jir.2011.0065
[5] LI P, ZHENG Y, CHEN X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics[J]. Front Pharmacol,2017,8:460. doi:  10.3389/fphar.2017.00460
[6] NIELSEN O H, AINSWORTH M A. Tumor necrosis factor inhibitors for inflammatory bowel disease[J]. N Engl J Med,2013,369(8):754-762. doi:  10.1056/NEJMct1209614
[7] TOUSSIROT É, AUBIN F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview[J]. RMD Open,2016,2(2):e000239. doi:  10.1136/rmdopen-2015-000239
[8] BRANDT J, LISTING J, HAIBEL H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis[J]. Rheumatology (Oxford),2005,44(3):342-348. doi:  10.1093/rheumatology/keh475
[9] ÜSKÜDAR CANSU D, ÜSKÜDAR TEKE H, TEMEL T, et al. Do anti-TNF agents increase the risk of inflammatory bowel disease evolution in patients with ankylosing spondylitis? real life data[J]. J Natl Med Assoc,2019,111(3):262-269. doi:  10.1016/j.jnma.2018.10.003
[10] HORIUCHI T, MITOMA H, HARASHIMA S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents[J]. Rheumatology (Oxford),2010,49(7):1215-1228. doi:  10.1093/rheumatology/keq031
[11] SCALLON B, CAI A, SOLOWSKI N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists[J]. J Pharmacol Exp Ther,2002,301(2):418-426. doi:  10.1124/jpet.301.2.418
[12] TOLU S, REZVANI A, HINDIOGLU N, et al. Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature[J]. Rheumatol Int,2018,38(11):2157-2162. doi:  10.1007/s00296-018-4165-3
[13] TOUSSIROT É, HOUVENAGEL É, GOËB V, et al. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series[J]. Joint Bone Spine,2012,79(5):457-463. doi:  10.1016/j.jbspin.2011.10.001